Fiduciam Capital is run by an experienced, energetic, and highly motivated operator who will relocate to join your management team. Fiduciam's investors and advisors have been owners, operators, and executives of dozens of companies in which they have created thousands of jobs and hundreds of millions of dollars of growth. The investors have more than 100 combined years of investing experience and bring serious, committed capital to the table to ensure a quick and successful closing. These experts will make up the board of the acquired company and will be involved with the ongoing guidance and growth of the company.
Bob Dahl is a founding Member of Arrowhawk Capital Partners, an investment management firm which manages a multi-strategy, institutionally-focused fund. From April 1999 until June 2006, Mr. Dahl served as the head of Global Healthcare for the Carlyle Group, a leading private equity firm with over $50 billion of equity under management, where he was responsible for the firm's investments in the healthcare field. During his tenure at Carlyle, Mr. Dahl served on the investment committee of the U.S. buyout funds, including the $7.9 billion Carlyle Partners IV and the $3.9 billion Carlyle Partners III funds. Mr. Dahl also served on the investment committee of the $430 million Carlyle Mezzanine Partners.
Prior to Carlyle, Mr. Dahl served as co-head of healthcare investment banking in North America at Credit Suisse First Boston. Earlier in his career Mr. Dahl was a CPA for Price Waterhouse. Mr. Dahl is a graduate of the Harvard Business School, where he was elected a Baker Scholar and received a Loeb Rhodes fellowship. He received a B.A. from Middlebury College. Mr. Dahl is a director of Amkai LLC and Applied Sciences, Inc.